Evidence map›Paper›PMID 24882635›Full record

ReviewFrontiers in neuroendocrinology2015

Estrogen-IGF-1 interactions in neuroprotection: ischemic stroke as a case study.

Farida Sohrabji

Open access · greenAbstract readReview
In one paragraph

Review in Frontiers in neuroendocrinology, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 38 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
38citing papers in PubMed, 1 pooled it
4.2field-weighted citation impact, top 6% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

38 citing papers in PubMed, 1 synthesis or guideline pooled it, 77 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Article
  4. Article
  5. Review
  6. Review
  7. Review
  8. Article
  9. Article
  10. Article
  11. Article
  12. Review
  13. Review
  14. Article
  15. Article
  16. Article
  17. Review
  18. Article
  19. Article
  20. CD271Experimental and therapeutic medicine · 2020
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

1 author at 1 institution in 1 country.

Farida SohrabjiWomen's Health in Neuroscience Program, Neuroscience and Experimental Therapeutics, TAMHSC College of Medicine, Bryan, TX 77807, United States. Electronic address: Sohrabji@medicine.tamhsc.edu.
Texas A&M Health Science Center · US

Funding

Epigenetics of the Aging Astrocyte: Implications for StrokeR01AG042189 · NIA · TEXAS A&M UNIVERSITY HEALTH SCIENCE CTR · PI Farida Sohrabji · 2011 to 2026
$3.1M
Epigenetics of the Aging Astrocyte: Implications for StrokeRF1AG042189 · NIA · TEXAS A&M UNIVERSITY · PI SOHRABJI, FARIDA · 2018 to 2018
$2.8M
Neuroprotection in the Aging Female BrainR01NS074895 · NINDS · TEXAS A&M UNIVERSITY HEALTH SCIENCE CTR · PI SOHRABJI, FARIDA · 2011 to 2015
$1.7M
Neuroprotection in the aging female brainR56NS074895 · NINDS · TEXAS A&M UNIVERSITY HEALTH SCIENCE CTR · PI SOHRABJI, FARIDA · 2017 to 2017
$520k
NIA NIH HHS AG042189NIA NIH HHS R01 AG042189NIA NIH HHS RF1 AG042189NINDS NIH HHS NS074895NINDS NIH HHS R01 NS074895NINDS NIH HHS R56 NS074895
6 · The paper itself

Abstract

The steroid hormone 17b-estradiol and the peptide hormone insulin-like growth factor (IGF)-1 independently exert neuroprotective actions in neurologic diseases such as stroke. Only a few studies have directly addressed the interaction between the two hormone systems, however, there is a large literature that indicates potentially greater interactions between the 17b-estradiol and IGF-1 systems. The present review focuses on key issues related to this interaction including IGF-1 and sex differences and common activation of second messenger systems. Using ischemic stroke as a case study, this review also focuses on independent and cooperative actions of estrogen and IGF-1 on neuroprotection, blood brain barrier integrity, angiogenesis, inflammation and post-stroke epilepsy. Finally, the review also focuses on the astrocyte, a key mediator of post stroke repair, as a local source of 17b-estradiol and IGF-1. This review thus highlights areas where significant new research is needed to clarify the interactions between these two neuroprotectants.

Indexed as

AnimalsAstrocytesBlood-Brain BarrierBrain IschemiaEstrogensHumansInsulin-Like Growth Factor INeuronsNeuroprotectionReceptor, IGF Type 1Receptors, EstrogenSex CharacteristicsStrokeEstrogensInsulin-Like Growth Factor IReceptor, IGF Type 1Receptors, EstrogenAstrocytesBlood brain barrierEstrogenIGF-1InflammationNeuroprotectionSex differences

Identifiers

PMID24882635
PMCPMC4247812
OpenAlexW2059810727

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.